IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00219583
First received: September 9, 2005
Last updated: November 5, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Assessment of efficacy and safety UK-390,957.
| Condition | Intervention | Phase |
|---|---|---|
| Ejaculation | Drug: UK-390,957 | Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment |
| Official Title: | A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation |
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Assessment of efficacy and safety
Secondary Outcome Measures:
- Assessment of quality of sexual life
| Estimated Enrollment: | 460 |
| Study Start Date: | August 2004 |
| Study Completion Date: | June 2005 |
| Primary Completion Date: | June 2005 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Premature ejaculation as defined by DSM-IV
Exclusion Criteria:
- History of erectile dysfunction
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00219583
Show 50 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00219583
Show 50 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00219583 History of Changes |
| Other Study ID Numbers: |
A3871027 |
| Study First Received: | September 9, 2005 |
| Last Updated: | November 5, 2012 |
Additional relevant MeSH terms:
|
Premature Ejaculation Sexual Dysfunction, Physiological Genital Diseases, Male Sexual Dysfunctions, Psychological Mental Disorders |
ClinicalTrials.gov processed this record on August 18, 2017